VCYT insider files Form 4 detailing November 2025 share sales

Q: What did the Veracyte (VCYT) Form 4 filing report?

The Form 4 reported that a Veracyte, Inc. director made three sales of Veracyte common stock on 11/20/2025 , and updated the director's remaining beneficial ownership.

Q: How many Veracyte (VCYT) shares did the director sell and at what prices?

The director sold 1,491 shares at a weighted average price of $40.9526 , 7,049 shares at $42.4765 , and 1,460 shares at $43.2095 , all on 11/20/2025 .

Q: How many Veracyte (VCYT) shares does the director own after the transactions?

Following the reported sales, the director beneficially owned 27,199 shares of Veracyte common stock, held in direct ownership.

Q: What do the weighted average prices mean in the Veracyte (VCYT) Form 4?

Each reported price is a weighted average sales price . The filing notes that the actual sale prices ranged from $40.86 to $41.20 , $41.89 to $42.89 , and $43.075 to $43.37 for the respective transactions.

Q: Can investors see the exact trade prices from this Veracyte (VCYT) insider sale?

The filing states that detailed information on the number of shares sold at each separate price will be provided to the SEC, the issuer, or a shareholder upon request.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Veracyte, Inc. (VCYT) director stock sale reported in a Form 4 filing. A company director filed as a single reporting person and disclosed three open‑market sales of Veracyte common stock on 11/20/2025, all coded as sales. The transactions, made pursuant to a Rule 10b5-1 plan adopted on August 21, 2025, involved 1,491 shares at a weighted average price of $40.9526, 7,049 shares at a weighted average price of $42.4765, and 1,460 shares at a weighted average price of $43.2095.

After these sales, the reporting person beneficially owned 27,199 shares of Veracyte common stock, held directly. The filing notes that each weighted average price represents multiple trades within specified price ranges, and more detailed breakdowns are available to the SEC, the issuer, or a shareholder upon request.

Insider Trade Summary

Net Seller: 10,000 shares ($423,563)

Net Sell 3 txns

Insider Holstein Jens

Role Director

Sold 10,000 shs ($424K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,491	$40.9526	$61K
Sale	Common Stock	7,049	$42.4765	$299K
Sale	Common Stock	1,460	$43.2095	$63K

Holdings After Transaction: Common Stock — 35,708 shares (Direct)

Footnotes (1)

The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025. Represents weighted average sales price. Sale prices for the transactions range from $40.86 to $41.20. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Represents weighted average sales price. Sale prices for the transactions range from $41.89 to $42.89. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Represents weighted average sales price. Sale prices for the transactions range from $43.075 to $43.37. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Form 4 Insider Transactions: What Each Field Means →

11/21/2025 - 04:19 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Holstein Jens

(Last)

(First)

(Middle)

6000 SHORELINE COURT

SUITE 300

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/20/2025		S⁽¹⁾		1,491	D	$40.9526⁽²⁾	35,708	D
Common Stock	11/20/2025		S⁽¹⁾		7,049	D	$42.4765⁽³⁾	28,659	D
Common Stock	11/20/2025		S⁽¹⁾		1,460	D	$43.2095⁽⁴⁾	27,199	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025.

2. Represents weighted average sales price. Sale prices for the transactions range from $40.86 to $41.20. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

3. Represents weighted average sales price. Sale prices for the transactions range from $41.89 to $42.89. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

4. Represents weighted average sales price. Sale prices for the transactions range from $43.075 to $43.37. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Remarks:

	/s/ Jonathan Wygant, as attorney-in-fact	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did the Veracyte (VCYT) Form 4 filing report?

The Form 4 reported that a Veracyte, Inc. director made three sales of Veracyte common stock on 11/20/2025, and updated the director's remaining beneficial ownership.

How many Veracyte (VCYT) shares did the director sell and at what prices?

The director sold 1,491 shares at a weighted average price of $40.9526, 7,049 shares at $42.4765, and 1,460 shares at $43.2095, all on 11/20/2025.

How many Veracyte (VCYT) shares does the director own after the transactions?

Following the reported sales, the director beneficially owned 27,199 shares of Veracyte common stock, held in direct ownership.

Was the Veracyte (VCYT) insider trading under a Rule 10b5-1 plan?

Yes. The filing states the transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025 and intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

What do the weighted average prices mean in the Veracyte (VCYT) Form 4?

Each reported price is a weighted average sales price. The filing notes that the actual sale prices ranged from $40.86 to $41.20, $41.89 to $42.89, and $43.075 to $43.37 for the respective transactions.

Can investors see the exact trade prices from this Veracyte (VCYT) insider sale?

The filing states that detailed information on the number of shares sold at each separate price will be provided to the SEC, the issuer, or a shareholder upon request.